Short answer
Anteris Technologies Global Corp. (AVR) filed its Q1 2026 10-Q quarterly report on May 12, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $494,000 (down 11.2% year over year) with net income of −$23M.
Q1 2026 key financials · XBRL
- Revenue
- $494,000
- −11.2% YoY
- Net income
- −$23M
- −5.3% YoY
- Operating margin
- -4859.7%
- EPS (diluted)
- −$0.28
- +54.1% YoY
Source: XBRL data from the Anteris Technologies Global Corp. (AVR) Q1 2026 10-Q on SEC EDGAR. USD.
Anteris Technologies Global Corp. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $494K, down 11% YoY from $556K, reflecting expired LeMaitre sales partly offset by higher 4C tissue-product sales
- Operating loss $24.0M vs $21.8M YoY, with R&D expense $17.5M and SG&A $6.9M
- Only segment: ADAPT tissue development and DurAVR THV System, with no segment-level profitability disclosed
- Cash $283.2M vs $12.6M at December 31, 2025; operating cash outflow $28.7M vs $21.5M YoY
- Financing provided $299.5M, including $308.3M net share-issuance proceeds; continued losses expected and additional funding may be required beyond current cash runway
Risk Factors
- Regulatory approval risk: FDA may revoke IDE approval, delay or deny PMA, or impose costly post-market controls on DurAVR THV System
- Clinical-development risk: PARADIGM Trial may fail despite FDA approval to begin the study
- Compliance and reputational risk: FDA enforcement, inquiries, or heightened scrutiny could deter physician adoption
- Near-term operating risk: Delayed or failed clearance could prevent revenue generation and profitability дости
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Anteris Technologies Global Corp. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.